Analysis of serum S-100 beta protein,NSE and neurological deficits in patients with cerebral infarction and reperfusion treated with butylphthalide / 中国基层医药

Objective To investigate the effects of butylphthalide on serum S-100 beta protein,NSE and neurological deficits in patients with cerebral infarction and reperfusion.Methods From January 2016 to January 2018,104 patients with early cerebral infarction admitted to the People's Hospital of Feicheng were divided into two groups according to different treatment methods.The control group (n =52) was given routine treatment,while the observation group (n =52) was given butylphthalide treatment on the basis of the control group.The degree of neurological deficit,serum NSE and S-100 beta protein levels were compared between the two groups before and after thrombolysis.Results The NIHSS scores of the two groups before thrombolysis were (10.27 ± 1.32) points and(10.28 ± 1.30) points,respectively,the difference between the two groups was no statistically significant(t =0.038,P ＞ 0.05).The NIHSS scores of the two groups were decreased at 24h and 7d after thrombolysis,which of the observation group at 24h and 7d after thrombolysis were (8.32 ± 1.37)points and (4.25 ± 1.54)points,respectively,which were significantly lower than those of the control group [(9.24 ± 1.40) points and (9.50 ± 1.24) points],the differences were statistically significant (t =3.396,19.147,all P ＜ 0.05).The serum NSE levels of the two groups before thrombolysis were (22.56 ± 5.78) U/mL and (22.58 ± 5.77) U/mL,respectively,the difference between the two groups was no statistically significant (t =0.017,P ＞ 0.05).At 24h and 7d after thrombolysis,the serum NSE levels of the two groups were decreased.The serum NSE levels of the observation group at 24h and 7d after thrombolysis were (15.08 ± 9.35) U/mL and (13.25 ± 6.47) U/mL,respectively,which were significantly lower than those in the control group [(18.96 ± 10.14)U/mL and (16.98 ± 7.11) U/mL],the differences were statistically significant(t =2.028,2.79,all P ＜ 0.05).The serum S-100β protein levels in the two groups before thrombolysis were(1.26 ± 0.71)μg/L and (1.27 ± 0.70)μg/L,respectively,and the difference was not significant (t =0.0723,P ＞0.05).At 24h and 7d after thrombolysis,the serum S-100β protein levels were decreased in both two groups,which in the observation group were (1.13 ± 0.62) μg/L and (0.53 ± 0.48) μg/L,respectively,which were significantly lower than those in the control group [(1.40 ± 0.64) μg/L,(0.87 ± 0.32) μg/L],the differences were statistically significant (t =2.185,4.25,all P ＜ 0.05).Conclusion Butylphthalide injection for patients with cerebral infarction and reperfusion can effectively promote the recovery of neurological function,improve the levels of serum NSE and S-100 beta protein,and help patients recover as soon as possible.

Clinical Value of Serum S100-beta Protein in the Diagnosis and Prognosis of Patients with Closed Craniocerebral Injury / 现代检验医学杂志

Objective To detect the level of S100-β protein in the serum of patients with closed craniocerebral injury and analyze its clinical value to assess the diagnosis and prognosis of the disease.Methods The expression of quantitative analysis method to detect 31 cases of healthy control group,40 cases of patients with severe craniocerebral injury and 34 cases of craniocerebral injury patients on admission S100-β protein level by the receiver operating characteristic curve (ROC) analysis,to explore the correlation between the prognosis of GOS,closed craniocerebral injury diagnosis efficacy.Results In the control group,mild and severe closed craniocerebral injury group S100-β protein levels were 0.137 ±0.025,0.192 ± 0.038 and 0.276 ±0.097 ng/ml,respectively.Compared with the control group (F=0.126,P=0.008),light and heavy closed craniocerebral injury group (F=38.17,P=0.001) of serum S100-β protein levels were significantly increased,the difference was statistically significant (P＜0.01).There were significant differences in the level of serum S100-β light and heavy craniocerebral injury group (P＜0.05).Serum S100-βprotein differential control group and brain injury group AUC 0.870 (95％ CI:0.776 ～ 0.964,P＜ 0.01).S100-β protein identification in healthy control group with severe craniocerebral injury group AUC was 0.914 (95 ％ CI:0.850～0.978,P＜ 0.01).The score was negatively correlated with serum S100-β protein level and the prognosis of craniocerebral injury in GOS (r=-0.792,P＜0.01).Conclusion S100-β protein significantly increased in serum of light and heavy closed craniocerebral injury patients,and negatively correlated with the GOS score of patients,can be used for the auxiliary diagnosis and prognosis of craniocerebral injury.

Relation between Serum S100beta and Severity and Prognosis in Traumatic Brain Injury

PURPOSE: S100beta, a marker of traumatic brain injury (TBI), has been increasingly focused upon during recent years. S100beta, is easily measured not only in cerebrospinal fluid (CSF) but also in serum. After TBI, serum S100beta, has been found to be increased at an early stage. The purpose of this study was to evaluate the clinical correlations between serum S100beta, and neurologic outcome, and severity in traumatic brain injury. METHODS: From August 2006 to October 2006, we made a protocol and studied prospectively 42 patients who visited the emergency room with TBI. Venous blood samples for S100beta, protein were taken within six hours after TBI and vital signs, as well as the Glasgow Coma Scale (GCS), were recorded. The final diagnosis and the severity were evaluated using the Abbreviated Injury Score (AIS), and the prognosis of the patients was evaluated using the Glasgow Outcome Score (GOS). RESULTS: Thirty-eight patients showed a favorable prognosis (discharge, recovery, transfer), and four showed an unfavorable prognosis. Serum S100beta, was higher in patients with an unfavorable prognosis than in patients with a favorable prognosis, and a significant difference existed between the two groups (0.74+/-50 microgram/L vs 7.62+/-6.53 microgram/L P=0.002). A negative correlation existed between serum S100beta, and the Revised Traumatic Score (R2=-0.34, P=0.03), and a positive correlation existed between serum S100beta, and the Injury Severity Score (R2=0.33, P=0.03). Furthermore, the correlations between serum S100beta, and the initial GCS and the GCS 24 hours after admission to the ER were negative (R2=-0.62, P<0.001; R2=-0.47, P=0.005). Regarding the GOS, the mean serum concentration of S100beta. was 7.62 beta partial differential/L (SD=+/-6.53) in the expired patients, 1.15 microgram/L in the mildly disable patient, and 0.727 microgram/L (SD=+/-0.73) in the recovered patients. These differences are statistically significant (p<0.001). CONCLUSION: In traumatic brain injury, a higher level of serum concentration of S100beta, has a poor prognosis for neurologic outcome.

Serum S100 beta Protein as a Marker of Cerebral Damage during Cardiopulmonary Bypass / 대한마취과학회지

BACKGROUND: S100 beta protein has been reported to be an early marker of brain injury. It is released from the glial cell and Schwann cell specifically after brain injury, and it,s serum concentration correlates with the severity of injury. The aim of this study was to measure the serum concentration of S100 beta protein during cardiac surgery and to reveal the correlation between cerebral oxygenation and S100 beta protein. METHODS: Eighteen patients undergoing cardiac surgery using cardiopulmonary bypass (CPB) were enrolled in this study. After induction of general anesthesia, the arterial-jugular venous oxygen difference (AjDO2), regional cerebral oxygen saturation (rSO2) and lactate oxygen index (LOI) were measured. They were measured after induction (T0), during CPB (T1) and at the end of CPB (T2). Serum S100beta protein was measured at T0, T2, T3 (5 hours after CPB), and T4 (24 hours after CPB) using an immunoluminometric assay. We observed correlations between rSO2, AjDO2, LOI and the S100beta protein concentration. RESULTS: Serum concentrations of S100 beta protein were 0.18 +/- 0.20, 5.72 +/- 4.25, 1.06 +/- 1.38 and 0.58 +/- 0.44 (micro gram/L) at T0, T2, T3 and T4 respectively (normal value